NASDAQ:BOLD - Audentes Therapeutics Stock Price, Price Target & More

$38.63 -0.29 (-0.75 %)
(As of 04/20/2018 12:42 PM ET)
Previous Close$38.92
Today's Range$38.01 - $39.06
52-Week Range$13.90 - $41.80
Volume86,370 shs
Average Volume434,461 shs
Market Capitalization$1.43 billion
P/E Ratio-11.45
Dividend YieldN/A
Beta1.39

About Audentes Therapeutics (NASDAQ:BOLD)

Audentes Therapeutics logoAudentes Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing gene therapy products for patients suffering from diseases caused by single gene defects. The company is developing AT132, which is in Phase I/II clinical studies for the treatment of X-linked myotubular myopathy (XLMTM); AT342 that is in Phase I/II clinical studies to treat crigler-najjar syndrome; AT982, which is in preclinical studies for the treatment of pompe disease; and AT307 that is in preclinical studies to treat CASQ2 subtype of catecholaminergic polymorphic ventricular tachycardia. Audentes Therapeutics, Inc. has a collaborative development agreement with Genethon to research, develop, manufacture, and commercialize products for the treatment of XLMTM; and license and collaboration agreement with the University of Pennsylvania to research, develop, sell, and import licensed products for the treatment of crigler-najjar. The company was founded in 2012 and is headquartered in San Francisco, California.

Receive BOLD News and Ratings via Email

Sign-up to receive the latest news and ratings for BOLD and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:BOLD
CUSIPN/A
Phone415-638-6556

Debt

Debt-to-Equity RatioN/A
Current Ratio7.74%
Quick Ratio7.74%

Price-To-Earnings

Trailing P/E Ratio-11.45
Forward P/E Ratio-11.26
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value($5.38) per share
Price / Book-7.18

Profitability

EPS (Most Recent Fiscal Year)($3.40)
Net Income$-90,230,000.00
Net MarginsN/A
Return on EquityN/A
Return on Assets-52.37%

Miscellaneous

Employees152
Outstanding Shares36,670,000

How to Become a New Pot Stock Millionaire

Audentes Therapeutics (NASDAQ:BOLD) Frequently Asked Questions

What is Audentes Therapeutics' stock symbol?

Audentes Therapeutics trades on the NASDAQ under the ticker symbol "BOLD."

How were Audentes Therapeutics' earnings last quarter?

Audentes Therapeutics (NASDAQ:BOLD) announced its quarterly earnings data on Thursday, March, 8th. The biotechnology company reported ($0.82) earnings per share for the quarter, beating analysts' consensus estimates of ($0.91) by $0.09. View Audentes Therapeutics' Earnings History.

When is Audentes Therapeutics' next earnings date?

Audentes Therapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, May, 9th 2018. View Earnings Estimates for Audentes Therapeutics.

What price target have analysts set for BOLD?

10 brokerages have issued 12-month target prices for Audentes Therapeutics' stock. Their forecasts range from $23.00 to $56.00. On average, they anticipate Audentes Therapeutics' share price to reach $35.3750 in the next year. View Analyst Ratings for Audentes Therapeutics.

Who are some of Audentes Therapeutics' key competitors?

Who are Audentes Therapeutics' key executives?

Audentes Therapeutics' management team includes the folowing people:
  • Mr. Matthew R. Patterson, Co-Founder, CEO, Pres & Director (Age 46)
  • Mr. Thomas P. Soloway, CFO and Sr. VP (Age 51)
  • Ms. Natalie C. Holles, Chief Operating Officer and Sr. VP (Age 45)
  • Dr. John T. Gray Ph.D., Chief Scientific Officer and Sr. VP (Age 55)
  • Ms. Dawn Blessing, VP of Corp. Devel.

When did Audentes Therapeutics IPO?

(BOLD) raised $75 million in an IPO on Wednesday, July 20th 2016. The company issued 5,000,000 shares at $14.00-$16.00 per share. BofA Merrill Lynch, Cowen and Company and Piper Jaffray acted as the underwriters for the IPO and Wedbush PacGrow was co-manager.

Has Audentes Therapeutics been receiving favorable news coverage?

Headlines about BOLD stock have trended somewhat positive this week, according to Accern. Accern identifies positive and negative press coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Audentes Therapeutics earned a media sentiment score of 0.06 on Accern's scale. They also assigned media stories about the biotechnology company an impact score of 47.06 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company's share price in the immediate future.

How do I buy shares of Audentes Therapeutics?

Shares of BOLD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Audentes Therapeutics' stock price today?

One share of BOLD stock can currently be purchased for approximately $38.63.

How big of a company is Audentes Therapeutics?

Audentes Therapeutics has a market capitalization of $1.43 billion. The biotechnology company earns $-90,230,000.00 in net income (profit) each year or ($3.40) on an earnings per share basis. Audentes Therapeutics employs 152 workers across the globe.

How can I contact Audentes Therapeutics?

Audentes Therapeutics' mailing address is 600 CALIFORNIA ST. 17TH FLOOR, SAN FRANCISCO CA, 94108. The biotechnology company can be reached via phone at 415-638-6556 or via email at [email protected]


MarketBeat Community Rating for Audentes Therapeutics (BOLD)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  138 (Vote Outperform)
Underperform Votes:  137 (Vote Underperform)
Total Votes:  275
MarketBeat's community ratings are surveys of what our community members think about Audentes Therapeutics and other stocks. Vote "Outperform" if you believe BOLD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BOLD will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Audentes Therapeutics (NASDAQ:BOLD) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
10 Wall Street analysts have issued ratings and price targets for Audentes Therapeutics in the last 12 months. Their average twelve-month price target is $35.3750, suggesting that the stock has a possible downside of 8.43%. The high price target for BOLD is $56.00 and the low price target for BOLD is $23.00. There are currently 2 hold ratings and 8 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.802.802.882.83
Ratings Breakdown: 0 Sell Rating(s)
2 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $35.3750$35.3750$36.7143$26.1667
Price Target Upside: 8.43% downside2.39% downside9.11% upside4.71% upside

Audentes Therapeutics (NASDAQ:BOLD) Consensus Price Target History

Price Target History for Audentes Therapeutics (NASDAQ:BOLD)

Audentes Therapeutics (NASDAQ:BOLD) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/9/2018CowenReiterated RatingBuyLowView Rating Details
3/9/2018WedbushReiterated RatingOutperform$56.00HighView Rating Details
3/9/2018HC WainwrightSet Price TargetBuy$37.00MediumView Rating Details
3/9/2018William BlairReiterated RatingBuyMediumView Rating Details
2/12/2018MizuhoInitiated CoverageNeutral -> Neutral$26.00MediumView Rating Details
1/5/2018BMO Capital MarketsSet Price TargetBuy$44.00HighView Rating Details
1/4/2018Raymond JamesReiterated RatingHoldHighView Rating Details
11/15/2017Leerink SwannReiterated RatingOutperform$22.00 -> $29.00N/AView Rating Details
9/22/2017Bank of AmericaReiterated RatingBuy$23.00 -> $33.00LowView Rating Details
8/16/2017Evercore ISIInitiated CoverageOutperform -> Outperform$23.00LowView Rating Details
11/12/2016Piper JaffraySet Price TargetBuy$24.00N/AView Rating Details
(Data available from 4/20/2016 forward)

Earnings

Audentes Therapeutics (NASDAQ:BOLD) Earnings History and Estimates Chart

Earnings by Quarter for Audentes Therapeutics (NASDAQ:BOLD)

Audentes Therapeutics (NASDAQ:BOLD) Earnings Estimates

2018 EPS Consensus Estimate: ($3.33)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20183($0.84)($0.78)($0.81)
Q2 20183($0.85)($0.80)($0.83)
Q3 20183($0.86)($0.81)($0.84)
Q4 20183($0.88)($0.83)($0.86)
Q1 20191($0.94)($0.94)($0.94)
Q2 20191($0.97)($0.97)($0.97)
Q4 20191($0.89)($0.89)($0.89)

Audentes Therapeutics (NASDAQ BOLD) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/9/2018($0.87)N/AView Earnings Details
3/8/2018Q4 2017($0.91)($0.82)ViewListenView Earnings Details
11/14/2017Q3 2017($0.88)($0.88)ViewN/AView Earnings Details
8/10/2017Q2 2017($0.77)($0.87)ViewN/AView Earnings Details
5/11/2017Q1 2017($0.92)($0.83)ViewN/AView Earnings Details
3/9/201712/31/2016($0.75)($0.91)ViewN/AView Earnings Details
11/10/2016Q3 2016($0.66)($0.94)ViewN/AView Earnings Details
8/31/2016Q2 2016($1.35)($6.43)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Audentes Therapeutics (NASDAQ:BOLD) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Audentes Therapeutics (NASDAQ BOLD) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 47.30%
Institutional Ownership Percentage: 66.96%
Insider Trading History for Audentes Therapeutics (NASDAQ:BOLD)
Institutional Ownership by Quarter for Audentes Therapeutics (NASDAQ:BOLD)

Audentes Therapeutics (NASDAQ BOLD) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
4/2/2018Matthew R PattersonCEOSell700$30.01$21,007.00700View SEC Filing  
3/29/2018Suyash PrasadVPSell7,800$30.03$234,234.007,800View SEC Filing  
3/26/2018Louis G LangeDirectorSell48,000$28.89$1,386,720.00414,231View SEC Filing  
3/26/2018Suyash PrasadVPSell1,900$30.00$57,000.001,900View SEC Filing  
3/15/2018Mary NewmanSVPSell10,000$30.36$303,600.004,076View SEC Filing  
3/12/2018Orbimed Advisors LlcMajor ShareholderSell156,431$34.97$5,470,392.07View SEC Filing  
3/8/2018Orbimed Advisors LlcMajor ShareholderSell58,428$34.06$1,990,057.68View SEC Filing  
3/6/2018Orbimed Advisors LlcMajor ShareholderSell433,210$35.11$15,210,003.10View SEC Filing  
3/2/2018Orbimed Advisors LlcMajor ShareholderSell421,638$35.17$14,829,008.46View SEC Filing  
12/22/2017Louis G LangeDirectorSell18,000$30.88$555,840.00View SEC Filing  
12/1/2017Suyash PrasadVPSell8,000$28.53$228,240.00View SEC Filing  
11/16/2017Mary NewmanSVPSell10,000$26.84$268,400.00View SEC Filing  
10/2/2017Matthew R PattersonCEOSell25,000$27.92$698,000.00View SEC Filing  
9/29/2017Louis G LangeDirectorSell11,000$28.35$311,850.00441,555View SEC Filing  
9/29/2017Orbimed Advisors LlcMajor ShareholderSell672,000$28.25$18,984,000.00View SEC Filing  
9/27/2017David NaglerSVPSell3,750$30.00$112,500.003,750View SEC Filing  
9/25/2017Louis G LangeDirectorSell18,000$28.32$509,760.00453,393View SEC Filing  
9/18/2017Matthew R PattersonCEOSell10,000$25.06$250,600.001,542View SEC Filing  
9/15/2017David NaglerSVPSell3,750$25.00$93,750.003,750View SEC Filing  
9/7/2017Orbimed Advisors LlcMajor ShareholderSell5,000$22.35$111,750.00View SEC Filing  
9/1/2017Suyash PrasadVPSell8,000$21.44$171,520.008,000View SEC Filing  
8/24/2017Mary NewmanSVPSell10,000$20.00$200,000.0010,000View SEC Filing  
7/13/2017Matthew R PattersonCEOSell15,000$20.00$300,000.00View SEC Filing  
7/12/2017Matthew R PattersonCEOSell2,850$20.00$57,000.00View SEC Filing  
6/26/2017Louis G LangeDirectorSell15,000$19.78$296,700.00470,799View SEC Filing  
4/24/20175Am Partners Iii, LlcInsiderBuy172,413$14.50$2,499,988.50View SEC Filing  
7/25/2016James E FlynnInsiderBuy400,000$15.00$6,000,000.00View SEC Filing  
7/25/2016Orbimed Advisors LlcDirectorBuy33,334$15.00$500,010.00View SEC Filing  
7/25/2016Versant Ventures Iv, LlcMajor ShareholderBuy35,000$15.00$525,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Audentes Therapeutics (NASDAQ BOLD) News Headlines

Source:
DateHeadline
Comparing Audentes Therapeutics (BOLD) & Biogen (BIIB)Comparing Audentes Therapeutics (BOLD) & Biogen (BIIB)
www.americanbankingnews.com - April 11 at 1:17 PM
Audentes Therapeutics (BOLD) Downgraded to Sell at ValuEngineAudentes Therapeutics (BOLD) Downgraded to Sell at ValuEngine
www.americanbankingnews.com - April 10 at 7:51 PM
First Week of BOLD November 16th Options TradingFirst Week of BOLD November 16th Options Trading
www.nasdaq.com - April 10 at 4:07 PM
Novartis takeout of AveXis stokes buying in gene therapy playersNovartis takeout of AveXis stokes buying in gene therapy players
seekingalpha.com - April 9 at 10:09 AM
Audentes Therapeutics (BOLD) Expected to Post Earnings of -$0.81 Per ShareAudentes Therapeutics (BOLD) Expected to Post Earnings of -$0.81 Per Share
www.americanbankingnews.com - April 7 at 9:55 AM
Audentes Therapeutics (BOLD) Coverage Initiated by Analysts at William BlairAudentes Therapeutics (BOLD) Coverage Initiated by Analysts at William Blair
www.americanbankingnews.com - April 6 at 10:54 PM
Audentes Therapeutics (BOLD) Raised to Hold at ValuEngineAudentes Therapeutics (BOLD) Raised to Hold at ValuEngine
www.americanbankingnews.com - April 5 at 2:14 PM
Audentes Therapeutics Inc (BOLD) CEO Matthew R. Patterson Sells 700 SharesAudentes Therapeutics Inc (BOLD) CEO Matthew R. Patterson Sells 700 Shares
www.americanbankingnews.com - April 4 at 11:37 PM
Audentes Therapeutics Inc (BOLD) SVP Sells $303,600.00 in StockAudentes Therapeutics Inc (BOLD) SVP Sells $303,600.00 in Stock
www.americanbankingnews.com - April 2 at 10:20 PM
Audentes Therapeutics (BOLD) Given a $37.00 Price Target at HC WainwrightAudentes Therapeutics (BOLD) Given a $37.00 Price Target at HC Wainwright
www.americanbankingnews.com - March 30 at 3:58 PM
Audentes Therapeutics Inc (BOLD) VP Sells $234,234.00 in StockAudentes Therapeutics Inc (BOLD) VP Sells $234,234.00 in Stock
www.americanbankingnews.com - March 29 at 10:46 PM
Insider Selling: Audentes Therapeutics Inc (BOLD) VP Sells 1,900 Shares of StockInsider Selling: Audentes Therapeutics Inc (BOLD) VP Sells 1,900 Shares of Stock
www.americanbankingnews.com - March 28 at 10:48 PM
Insider Selling: Audentes Therapeutics Inc (BOLD) Director Sells 48,000 Shares of StockInsider Selling: Audentes Therapeutics Inc (BOLD) Director Sells 48,000 Shares of Stock
www.americanbankingnews.com - March 28 at 10:31 PM
Audentes Therapeutics (BOLD) PT Set at $37.00 by HC WainwrightAudentes Therapeutics (BOLD) PT Set at $37.00 by HC Wainwright
www.americanbankingnews.com - March 28 at 8:42 PM
Audentes Therapeutics Inc (BOLD) Receives Average Recommendation of "Buy" from AnalystsAudentes Therapeutics Inc (BOLD) Receives Average Recommendation of "Buy" from Analysts
www.americanbankingnews.com - March 27 at 1:39 AM
Audentes Therapeutics Inc (BOLD) Expected to Post Earnings of -$0.81 Per ShareAudentes Therapeutics Inc (BOLD) Expected to Post Earnings of -$0.81 Per Share
www.americanbankingnews.com - March 21 at 12:36 PM
Edited Transcript of BOLD earnings conference call or presentation 8-Mar-18 9:30pm GMTEdited Transcript of BOLD earnings conference call or presentation 8-Mar-18 9:30pm GMT
finance.yahoo.com - March 18 at 9:48 AM
Audentes Therapeutics (BOLD) Downgraded by BidaskClubAudentes Therapeutics (BOLD) Downgraded by BidaskClub
www.americanbankingnews.com - March 17 at 7:16 PM
Audentes Therapeutics (BOLD) Stock Rating Lowered by Zacks Investment ResearchAudentes Therapeutics (BOLD) Stock Rating Lowered by Zacks Investment Research
www.americanbankingnews.com - March 13 at 5:48 PM
Audentes Therapeutics Inc (BOLD) Major Shareholder Sells $1,990,057.68 in StockAudentes Therapeutics Inc (BOLD) Major Shareholder Sells $1,990,057.68 in Stock
www.americanbankingnews.com - March 12 at 7:21 PM
Audentes Therapeutics Inc (BOLD) Major Shareholder Orbimed Advisors Llc Sells 156,431 SharesAudentes Therapeutics Inc (BOLD) Major Shareholder Orbimed Advisors Llc Sells 156,431 Shares
www.americanbankingnews.com - March 12 at 7:21 PM
Brokers Offer Predictions for Audentes Therapeutics Incs FY2022 Earnings (BOLD)Brokers Offer Predictions for Audentes Therapeutics Inc's FY2022 Earnings (BOLD)
www.americanbankingnews.com - March 12 at 10:02 AM
Audentes Therapeutics Inc to Post Q1 2019 Earnings of ($0.94) Per Share, William Blair Forecasts (BOLD)Audentes Therapeutics Inc to Post Q1 2019 Earnings of ($0.94) Per Share, William Blair Forecasts (BOLD)
www.americanbankingnews.com - March 12 at 7:12 AM
Audentes Therapeutics (BOLD) Buy Rating Reaffirmed at William BlairAudentes Therapeutics' (BOLD) Buy Rating Reaffirmed at William Blair
www.americanbankingnews.com - March 10 at 4:20 PM
Wedbush Reiterates Outperform Rating for Audentes Therapeutics (BOLD)Wedbush Reiterates Outperform Rating for Audentes Therapeutics (BOLD)
www.americanbankingnews.com - March 9 at 6:13 PM
Audentes Therapeutics (BOLD) Rating Reiterated by CowenAudentes Therapeutics (BOLD) Rating Reiterated by Cowen
www.americanbankingnews.com - March 9 at 4:54 PM
Audentes Therapeutics (BOLD) Releases  Earnings Results, Beats Estimates By $0.09 EPSAudentes Therapeutics (BOLD) Releases Earnings Results, Beats Estimates By $0.09 EPS
www.americanbankingnews.com - March 9 at 10:35 AM
Audentes Therapeutics (BOLD) Upgraded to Buy by Zacks Investment ResearchAudentes Therapeutics (BOLD) Upgraded to Buy by Zacks Investment Research
www.americanbankingnews.com - March 8 at 6:41 PM
Audentes Therapeutics Reports Fourth Quarter 2017 and Full Year Financial Results and Provides Corporate UpdateAudentes Therapeutics Reports Fourth Quarter 2017 and Full Year Financial Results and Provides Corporate Update
www.prnewswire.com - March 8 at 4:49 PM
Is a Surprise Coming for Audentes Therapeutics (BOLD) This Earnings Season?Is a Surprise Coming for Audentes Therapeutics (BOLD) This Earnings Season?
finance.yahoo.com - March 7 at 10:04 AM
Orbimed Advisors Llc Sells 433,210 Shares of Audentes Therapeutics Inc (BOLD) StockOrbimed Advisors Llc Sells 433,210 Shares of Audentes Therapeutics Inc (BOLD) Stock
www.americanbankingnews.com - March 6 at 6:16 PM
Orbimed Advisors Llc Sells 421,638 Shares of Audentes Therapeutics Inc (BOLD) StockOrbimed Advisors Llc Sells 421,638 Shares of Audentes Therapeutics Inc (BOLD) Stock
www.americanbankingnews.com - March 6 at 6:16 PM
Audentes Therapeutics to Present at the Cowen 38th Annual Health Care ConferenceAudentes Therapeutics to Present at the Cowen 38th Annual Health Care Conference
finance.yahoo.com - March 6 at 9:50 AM
-$0.92 EPS Expected for Audentes Therapeutics Inc (BOLD) This Quarter-$0.92 EPS Expected for Audentes Therapeutics Inc (BOLD) This Quarter
www.americanbankingnews.com - March 4 at 5:10 AM
Ascend Capital LLC Cuts Holdings in Audentes Therapeutics Inc (BOLD)Ascend Capital LLC Cuts Holdings in Audentes Therapeutics Inc (BOLD)
www.americanbankingnews.com - March 2 at 5:06 AM
Audentes Therapeutics Inc (BOLD) Given Consensus Rating of "Buy" by BrokeragesAudentes Therapeutics Inc (BOLD) Given Consensus Rating of "Buy" by Brokerages
www.americanbankingnews.com - March 2 at 1:32 AM
Audentes Therapeutics to Release Fourth Quarter and Full Year 2017 Financial Results and Provide Corporate Update on Thursday, March 8, 2018Audentes Therapeutics to Release Fourth Quarter and Full Year 2017 Financial Results and Provide Corporate Update on Thursday, March 8, 2018
finance.yahoo.com - March 1 at 9:34 AM
Audentes Therapeutics Inc (BOLD) Shares Bought by Spark Investment Management LLCAudentes Therapeutics Inc (BOLD) Shares Bought by Spark Investment Management LLC
www.americanbankingnews.com - February 28 at 5:44 PM
Audentes Therapeutics Joins Global Organizations In Recognizing Rare Disease Day® 2018Audentes Therapeutics Joins Global Organizations In Recognizing Rare Disease Day® 2018
finance.yahoo.com - February 28 at 9:50 AM
Audentes Therapeutics Inc (BOLD) Expected to Post Earnings of -$0.92 Per ShareAudentes Therapeutics Inc (BOLD) Expected to Post Earnings of -$0.92 Per Share
www.americanbankingnews.com - February 15 at 11:10 AM
Audentes Therapeutics (BOLD) Coverage Initiated by Analysts at MizuhoAudentes Therapeutics (BOLD) Coverage Initiated by Analysts at Mizuho
www.americanbankingnews.com - February 12 at 8:28 PM
Audentes Therapeutics Announces Dosing of First Patient in VALENS, a Phase 1/2 Clinical Trial of AT342 for the treatment of Crigler-Najjar SyndromeAudentes Therapeutics Announces Dosing of First Patient in VALENS, a Phase 1/2 Clinical Trial of AT342 for the treatment of Crigler-Najjar Syndrome
finance.yahoo.com - February 12 at 8:49 AM
Short Interest in Audentes Therapeutics Inc (BOLD) Rises By 71.6%Short Interest in Audentes Therapeutics Inc (BOLD) Rises By 71.6%
www.americanbankingnews.com - February 11 at 1:52 AM
Audentes Therapeutics (BOLD) Rating Increased to Hold at Zacks Investment ResearchAudentes Therapeutics (BOLD) Rating Increased to Hold at Zacks Investment Research
www.americanbankingnews.com - February 9 at 7:16 PM
Audentes Therapeutics to Present at the LEERINK Partners 7th Annual Global Healthcare ConferenceAudentes Therapeutics to Present at the LEERINK Partners 7th Annual Global Healthcare Conference
finance.yahoo.com - February 8 at 9:12 AM
Audentes Therapeutics (BOLD) Earns Buy Rating from HC WainwrightAudentes Therapeutics (BOLD) Earns Buy Rating from HC Wainwright
www.americanbankingnews.com - February 8 at 12:12 AM
Audentes Therapeutics Inc (BOLD) Receives Consensus Rating of "Buy" from AnalystsAudentes Therapeutics Inc (BOLD) Receives Consensus Rating of "Buy" from Analysts
www.americanbankingnews.com - February 5 at 1:28 AM
Gene therapy stocks tank after leading scientist reveals safety concerns; Solid Bioscience down 15%Gene therapy stocks tank after leading scientist reveals safety concerns; Solid Bioscience down 15%
www.marketwatch.com - January 30 at 4:46 PM
Audentes Therapeutics Announces the Closing of its Public Offering and Full Exercise of the Underwriters Option to Purchase Additional SharesAudentes Therapeutics Announces the Closing of its Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares
finance.yahoo.com - January 29 at 4:43 PM
Audentes Therapeutics Announces Proposed Public Offering of Common StockAudentes Therapeutics Announces Proposed Public Offering of Common Stock
finance.yahoo.com - January 23 at 4:23 PM

SEC Filings

Audentes Therapeutics (NASDAQ:BOLD) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Audentes Therapeutics (NASDAQ:BOLD) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Audentes Therapeutics (NASDAQ BOLD) Stock Chart for Friday, April, 20, 2018

Loading chart…

This page was last updated on 4/20/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.